Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab

Ian D. Pavord; Roland Buhl; Monica Kraft; Charlene M. Prazma; Robert G. Price; Peter H. Howarth; Steven W. Yancey

doi:10.1183/23120541.00560-2021

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab

Ian D. Pavord
, Roland Buhl
, Monica Kraft
, Charlene M. Prazma
, Robert G. Price
, Peter H. Howarth
, Steven W. Yancey

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Article number	00560-2021
Journal	ERJ Open Research
Volume	8
Issue number	2
DOIs	https://doi.org/10.1183/23120541.00560-2021
State	Published - Apr 1 2022

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1183/23120541.00560-2021

Cite this

@article{5fc0e04711b04902a101adfa07060385,

title = "Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab",

author = "Pavord, \{Ian D.\} and Roland Buhl and Monica Kraft and Prazma, \{Charlene M.\} and Price, \{Robert G.\} and Howarth, \{Peter H.\} and Yancey, \{Steven W.\}",

note = "Funding Information: Support statement: This post hoc analysis and the parent study (GlaxoSmithKline (GSK) identifier MEA112997; www.clinicaltrials.gov identifier NCT01366521) were funded by GSK. Editorial support (in the form of writing assistance, including preparation of the draft manuscript under the direction and guidance of the authors, collating and incorporating authors{\textquoteright} comments for each draft, assembling tables and figures, grammatical editing and referencing) was provided by Bianca Paris, PhD, of Fishawack Indicia Ltd, part of Fishawack Health, and funded by GSK. Funding information for this article has been deposited with the Crossref Funder Registry.",

year = "2022",

month = apr,

day = "1",

doi = "10.1183/23120541.00560-2021",

language = "English (US)",

volume = "8",

journal = "ERJ Open Research",

issn = "2312-0541",

publisher = "European Respiratory Society",

number = "2",

}

TY - JOUR

T1 - Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab

AU - Pavord, Ian D.

AU - Buhl, Roland

AU - Kraft, Monica

AU - Prazma, Charlene M.

AU - Price, Robert G.

AU - Howarth, Peter H.

AU - Yancey, Steven W.

N1 - Funding Information: Support statement: This post hoc analysis and the parent study (GlaxoSmithKline (GSK) identifier MEA112997; www.clinicaltrials.gov identifier NCT01366521) were funded by GSK. Editorial support (in the form of writing assistance, including preparation of the draft manuscript under the direction and guidance of the authors, collating and incorporating authors’ comments for each draft, assembling tables and figures, grammatical editing and referencing) was provided by Bianca Paris, PhD, of Fishawack Indicia Ltd, part of Fishawack Health, and funded by GSK. Funding information for this article has been deposited with the Crossref Funder Registry.

PY - 2022/4/1

Y1 - 2022/4/1

UR - https://www.scopus.com/pages/publications/85130765314

UR - https://www.scopus.com/pages/publications/85130765314#tab=citedBy

U2 - 10.1183/23120541.00560-2021

DO - 10.1183/23120541.00560-2021

M3 - Letter

AN - SCOPUS:85130765314

SN - 2312-0541

VL - 8

JO - ERJ Open Research

JF - ERJ Open Research

IS - 2

M1 - 00560-2021

ER -

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this